Literature DB >> 16410445

In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.

Marc Beyer1, Matthias Kochanek, Thomas Giese, Elmar Endl, Martin R Weihrauch, Percy A Knolle, Sabine Classen, Joachim L Schultze.   

Abstract

In solid tumors, leukemias, and lymphomas, increased frequencies of functional CD4+CD25(high) regulatory T cells (T(reg) cells) have been previously demonstrated. In healthy individuals, T(reg) cells consist not only of memory but also of naive T cells, which can undergo peripheral expansion and are characterized by a relative enrichment for autoreactive T-cell receptors. Here, we demonstrate in patients with premalignant monoclonal gammopathy of undetermined significance and patients with multiple myeloma that functional FoxP3(+) T(reg) cells of naive, central, and effector memory phenotype as determined by CCR7 and CD45RA expression are significantly expanded. Low frequencies of T-cell receptor excision circles in naive T(reg) cells in both healthy controls and multiple myeloma patients point to peripheral expansion as the prominent mechanism of increased frequencies of naive T(reg) cells in these cancer patients. These findings strongly suggest that the increase of functional T(reg) cells in cancer patients is a response to the process of malignant transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16410445     DOI: 10.1182/blood-2005-09-3671

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

1.  Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2.

Authors:  Guangxian Liu; Wuwei Yang; Mei Guo; Xiaoqing Liu; Naixiang Huang; Dingfeng Li; Zefei Jiang; Wenfeng Yang; Weijing Zhang; Hang Su; Zhiqing Liu; Tieqiang Liu; Dongmei Wang; Shan Huang; Bo Yao; Qiuhong Man; Lijuan Qiu; Xuedong Sun; Yuying Sun; Bing Liu
Journal:  Cancer Immunol Immunother       Date:  2012-06-22       Impact factor: 6.968

2.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

4.  Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.

Authors:  J Bae; T Hideshima; G L Zhang; J Zhou; D B Keskin; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

Review 5.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

6.  A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Authors:  Don M Benson; Craig C Hofmeister; Swaminathan Padmanabhan; Attaya Suvannasankha; Sundar Jagannath; Rafat Abonour; Courtney Bakan; Pascale Andre; Yvonne Efebera; Jérôme Tiollier; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

7.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

8.  Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Authors:  Eva Rossmann; Anders Österborg; Eva Löfvenberg; Aniruddha Choudhury; Ulf Forssmann; Anja von Heydebreck; Andreas Schröder; Håkan Mellstedt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells.

Authors:  Weiyun Z Ai; Jing-Zhou Hou; Robert Zeiser; Debra Czerwinski; Robert S Negrin; Ronald Levy
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

Review 10.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.